Patents by Inventor Peter Campochiaro

Peter Campochiaro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050209237
    Abstract: Disclosed herein are methods for decreasing or attenuating an increase in capillary permeability in the retina in a subject in need of such treatment, comprising administering a composition comprising an amount of a phthalazine derivative or a salt thereof to a subject suffering from excessive or pathological capillary permeability in the retina, the amount of phthalazine derivative or salt thereof being effective to decrease the permeability of capillaries in the retina of the subject, in particular where the subject is suffering from macular edema.
    Type: Application
    Filed: April 29, 2003
    Publication date: September 22, 2005
    Inventors: Romulus Brazzell, Kenneth Green, Frances Kane, Peter Campochiaro
  • Publication number: 20050175617
    Abstract: The invention provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.
    Type: Application
    Filed: March 4, 2005
    Publication date: August 11, 2005
    Inventors: Stanley Wiegand, Peter Campochiaro, George Yancopoulos
  • Publication number: 20040116409
    Abstract: Methods for the treatment of a subject suffering from ERM formation or retinal detachment due to ERM formation comprising administering to a subject suffering from ERM formation or retinal detachment due to ERM formation an effective amount of a staurosporine derivative to treat ERM formation or retinal detachment in the eye of the subject, or a salt thereof, are provided.
    Type: Application
    Filed: November 6, 2003
    Publication date: June 17, 2004
    Inventor: Peter A. Campochiaro
  • Publication number: 20040116434
    Abstract: A method for treating a subject suffering from epiretinal membrane formation or retinal detachment due to epiretinal membrane formation is disclosed.
    Type: Application
    Filed: November 7, 2003
    Publication date: June 17, 2004
    Inventor: Peter A. Campochiaro
  • Publication number: 20040102444
    Abstract: The invention relates to methods for the delivery of certain phthalazine derivatives to the retina(s) of a subject in need of treatment.
    Type: Application
    Filed: September 16, 2003
    Publication date: May 27, 2004
    Inventors: Peter Campochiaro, Michelle Wong, Shau-fong Yen
  • Publication number: 20030158112
    Abstract: The invention is directed to a method of prophylactically or therapeutically treating choroidal neovascularization, wherein the method comprises directly administering to the eye a therapeutic factor or a nucleic acid sequence that encodes a therapeutic factor, which he expressed to produce the therapeutic factor, to selectively induce apoptosis of endothelial cells associated with neovascularization of the choroid such that choroidal neovascularization is treated prophylactically or therapeutically. The invention also provides a method of prophylactically or therapeutically treating ocular neovascularization, wherein the method comprises directly administering to the eye a nucleic acid sequence encoding a therapeutic factor to promote apoptosis of endothelial cells associated with neovascularization, such that the nucleic acid is expressed thereby producing the therapeutic factor to treat ocular neovascularization prophylactically or therapeutically.
    Type: Application
    Filed: February 14, 2003
    Publication date: August 21, 2003
    Applicant: Johns Hopkins University School of Medicine
    Inventor: Peter A. Campochiaro
  • Patent number: 6573271
    Abstract: Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 &mgr;g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.
    Type: Grant
    Filed: September 11, 2001
    Date of Patent: June 3, 2003
    Assignees: John Hopkins University School of Medicine, The Allergan
    Inventors: Peter A. Campochiaro, Larry A. Wheeler, Roshantha A. Chandraratna, Sunil Nagpal, Eugene De Juan, Jr.
  • Publication number: 20030040463
    Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptorbody which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.
    Type: Application
    Filed: July 1, 2002
    Publication date: February 27, 2003
    Inventors: Stanley J. Wiegand, Peter A. Campochiaro, George D. Yancopoulos
  • Patent number: 6479729
    Abstract: Transgenic mammals are provided which develop neovascularization of the retina, similar to that found in a variety of disease states, including diabetes, age related macular degeneration, retinopathy of prematurity, sickle cell retinopathy. These mammals can be used as test systems to evaluate potential prophylactic and therapeutic regimens. The effect of a regimen on the neovascularization is indicative of its beneficial effect in a disease state which is associated with neovascularization.
    Type: Grant
    Filed: June 5, 2000
    Date of Patent: November 12, 2002
    Assignee: The Johns Hopkins University
    Inventors: Peter A. Campochiaro, Donald J. Zack
  • Publication number: 20020128291
    Abstract: Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 &mgr;g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.
    Type: Application
    Filed: September 11, 2001
    Publication date: September 12, 2002
    Applicant: Allergan, California corporation
    Inventors: Peter A. Campochiaro, Larry A. Wheeler, Roshantha A. Chandraratna, Sunil Nagpal, Eugene De Juan
  • Patent number: 6372753
    Abstract: Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 &mgr;g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.
    Type: Grant
    Filed: March 27, 2000
    Date of Patent: April 16, 2002
    Assignees: Allergan, The Johns Hopkins University School of Medicine
    Inventors: Peter A. Campochiaro, Larry A. Wheeler, Roshantha A. Chandraratna, Sunil Nagpal, Eugene De Juan, Jr.
  • Publication number: 20020006967
    Abstract: The present invention includes methods for treatment and prophylaxis of eye disorders and injuries, particularly treatment and prophylaxis of ocular neovascularization and disorders, especially a vasculopathy that affects retinal or chorodial vessels. The methods of the invention in general comprise administration of a therapeutically effective amount of a compound that inhibits farnesyl-protein transferase to a subject suffering from or susceptible to ocular neovascularization or associated disorder.
    Type: Application
    Filed: June 18, 1998
    Publication date: January 17, 2002
    Inventor: PETER A. CAMPOCHIARO
  • Patent number: 6075032
    Abstract: Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 .mu.g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: June 13, 2000
    Assignees: Allergan, Johns Hopkins University School of Medicine
    Inventors: Peter A. Campochiaro, Larry A. Wheeler, Roshantha A. Chandraratna, Sunil Nagpal, Eugene De Juan, Jr.
  • Patent number: 6071924
    Abstract: Proliferation of retinal pigment epithelium following surgery or trauma is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR) agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epitelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 .mu.g, or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.
    Type: Grant
    Filed: October 20, 1998
    Date of Patent: June 6, 2000
    Assignees: Allergan, Johns Hopkins University School of Medicine
    Inventors: Peter A. Campochiaro, Larry A. Wheeler, Roshantha A. Chandraratna, Sunil Nagpal
  • Patent number: 5824685
    Abstract: Proliferation of retinal pigment epithelium following surgery or trauma is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR) agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epitelium is ameliorated witha therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 .mu.g, or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.
    Type: Grant
    Filed: February 1, 1995
    Date of Patent: October 20, 1998
    Assignees: The Johns Hopkins University School of Medicine, Allergan
    Inventors: Peter A. Campochiaro, Larry A. Wheeler, Roshantha A. Chandraratna, Sunil Nagpal